AGN

Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024

Retrieved on: 
Thursday, April 11, 2024
Q & A, Interview, AGN, DMT

VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), is pleased to invite investors and other interested parties to participate in an upcoming special CEO interview and Q & A session on April 16th, 2024, at 4 PM ET / 1 PM PT, hosted by Market Radius Research.

Key Points: 
  • VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), is pleased to invite investors and other interested parties to participate in an upcoming special CEO interview and Q & A session on April 16th, 2024, at 4 PM ET / 1 PM PT, hosted by Market Radius Research.
  • Martin Gagel of Market Radius Research and CEO Christopher J. Moreau will discuss the recent Ifendprodil transaction with Seyltx and the plans and milestones in store for Algernon's DMT stroke research program in 2024 and beyond.
  • The webinar will be a live, interactive online event where attendees are invited to ask the CEO questions in real-time, following the interview.
  • An archived webcast will be made available for those who cannot join the event live on the day of the webinar.

Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset

Retrieved on: 
Monday, April 1, 2024
Neuroplasticity, Stroke, Diagnosis, Depression, Plasma, CHDR, Rat, Patient, Research, Biomarker, DMT, AGN, Ifenprodil, Brain, Clinical trial, Safety, Algernon, USD, Pharmaceutical industry

Algernon established Algernon NeuroScience (AGN Neuro), a wholly owned subsidiary, to advance the research and development of the DMT stroke program in 2023.

Key Points: 
  • Algernon established Algernon NeuroScience (AGN Neuro), a wholly owned subsidiary, to advance the research and development of the DMT stroke program in 2023.
  • AGN Neuro has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2a DMT Stroke study.
  • The Phase 2a human stroke trial will study an intravenous sub-psychedelic dose of DMT in patients who are hospitalized after having suffered an acute ischemic stroke.
  • “Algernon is a global leader in this important area of research, and we look forward to further advancing the stroke program through our planned Phase 2a DMT Stroke study.”
    Subjects with a confirmed diagnosis of ischemic stroke will be randomized in blinded fashion to receive either DMT or placebo.

Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

Retrieved on: 
Wednesday, March 27, 2024
Algernon, Brain, Drug discovery, Letter, NMDA, Acquisition, Patient, AGN, Ifenprodil, IPF, Idiopathic pulmonary fibrosis, USD, Chronic cough, Food, Pharmaceutical industry

The Company previously announced on November 22, 2003 that it had signed a Letter of Intent with Seyltx, to acquire Algernon’s Ifenprodil research program.

Key Points: 
  • The Company previously announced on November 22, 2003 that it had signed a Letter of Intent with Seyltx, to acquire Algernon’s Ifenprodil research program.
  • Ifenprodil is an N-methyl-D-aspartate (“NMDA”) receptor antagonist specifically targeting the NMDA type subunit 2B (GluN2B), which prevents glutamate signaling.
  • Ifenprodil is one of Algernon’s lead research programs and represents a novel first-in-class potential treatment for chronic cough.
  • It is thought to interfere with central signalling in the brain, suppressing the urge to cough.

ALAMO GROUP INC. ANNOUNCES RETIREMENT OF BOARD MEMBER, APPOINTMENT OF NEW BOARD CHAIR AND APPOINTMENT OF NEW DIRECTOR

Retrieved on: 
Thursday, February 22, 2024
Engineering, International, ALG, Retirement, Air Products, Battle of the Alamo, AGN, Management

Mr. Baty joined the Board in August 2011 and has served in various capacities during his tenure.

Key Points: 
  • Mr. Baty joined the Board in August 2011 and has served in various capacities during his tenure.
  • Mr. Baty was appointed Independent Board Chair on May 3, 2018.
  • Upon Mr. Baty's retirement from the Board, current Board member, Richard ("Rick") W. Parod, will be appointed the new Independent Board Chair effective April 30, 2024.
  • We are excited for Rick to step in as the new Independent Board Chair.

Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD

Retrieved on: 
Wednesday, January 31, 2024
UUO, Kidney disease, CKD, AGN, Fibrosis, RSU, Patent, Chronic kidney disease, Telmisartan, Pharmaceutical industry

VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has received a notice of intention to grant from the Chinese Patent Office for patent application No.

Key Points: 
  • VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has received a notice of intention to grant from the Chinese Patent Office for patent application No.
  • The base claims of the patent will be valid through 2038, excluding any patent term adjustments or extensions, which may provide additional protection.
  • The Company was recently issued patents for Repirinast in chronic kidney disease (CKD) from Japan and has also filed corresponding patent applications in Canada, Europe and the United States.
  • “We are once again pleased to receive another notice of intent to grant a patent from the Chinese Patent Office,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals.

Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis

Retrieved on: 
Thursday, January 11, 2024
Idiopathic pulmonary fibrosis, IPF, Patent, AGN, Pharmaceutical industry

VANCOUVER, British Columbia, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company is pleased to announce that it has received a notice of allowance from the Japanese Patent Office for patent application No.

Key Points: 
  • VANCOUVER, British Columbia, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company is pleased to announce that it has received a notice of allowance from the Japanese Patent Office for patent application No.
  • 2021-547495 entitled: Compositions and Methods for Treating Idiopathic Pulmonary Fibrosis (IPF).
  • The Company was previously granted a patent for the treatment of IPF in Canada and has also filed corresponding patent applications in the U.S., Europe, and China.
  • “The invention claims treating interstitial lung disease, including idiopathic pulmonary fibrosis, with ifenprodil”, said Christopher J. Moreau, CEO of Algernon.

Algernon Pharmaceuticals Announces Closing of Private Placement

Retrieved on: 
Wednesday, December 27, 2023
AGN, Minority, Indian stock exchange, Multilateral, Unit, Offering

VANCOUVER, British Columbia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces the close of its non-brokered private placement, previously announced on December 12, 2023 and updated on December 27, 2023, for gross proceeds of $280,000 (the “Offering”) of units (the “Units”) at an issue price of $0.075 per Unit.

Key Points: 
  • VANCOUVER, British Columbia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces the close of its non-brokered private placement, previously announced on December 12, 2023 and updated on December 27, 2023, for gross proceeds of $280,000 (the “Offering”) of units (the “Units”) at an issue price of $0.075 per Unit.
  • Certain insiders of the Company participated in the Offering in the amount of $173,505.
  • The participation by insiders in the Offering constitutes a "related party transaction" as defined under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions ("MI 61-101").
  • The Company will use the proceeds of the private placement for working capital purposes.

Algernon Pharmaceuticals Announces Increase to Private Placement

Retrieved on: 
Wednesday, December 27, 2023
Regulation, Indian stock exchange, AGN, Legislation, Exercise, News, Warrant, Expiration date, Acceleration, Security (finance)

VANCOUVER, British Columbia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces an increase to its non-brokered private placement, previously announced on December 12, 2023, from gross proceeds of $150,000 to $280,000 (the “Offering”) of units (the “Units”) at an issue price of $0.075 per Unit.

Key Points: 
  • VANCOUVER, British Columbia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces an increase to its non-brokered private placement, previously announced on December 12, 2023, from gross proceeds of $150,000 to $280,000 (the “Offering”) of units (the “Units”) at an issue price of $0.075 per Unit.
  • Each Unit will consist of one Class A common share in the capital of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”).
  • The Company will use the proceeds of the private placement for working capital purposes.
  • The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S.

Algernon Pharmaceuticals Announces Private Placement

Retrieved on: 
Wednesday, December 13, 2023
Regulation, Indian stock exchange, AGN, Legislation, Exercise, News, Warrant, Expiration date, Acceleration, Security (finance)

VANCOUVER, British Columbia, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces a non-brokered private placement for gross proceeds of $150,000 (the “Offering”) of units (the “Units”) at an issue price of $0.075 per Unit.

Key Points: 
  • VANCOUVER, British Columbia, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces a non-brokered private placement for gross proceeds of $150,000 (the “Offering”) of units (the “Units”) at an issue price of $0.075 per Unit.
  • Each Unit will consist of one Class A common share in the capital of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”).
  • The Company will use the proceeds of the private placement for working capital purposes.
  • The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S.

Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD

Retrieved on: 
Thursday, November 30, 2023
NAFLD, Risk, NASH, Fatty liver disease, AGN, Type, Inflammation, Standard of care, Patent, Insulin resistance, Laboratory, Obesity, Patient, Telmisartan, Steatosis, Fibrosis, UUO, CKD, Pharmaceutical industry

The invention claims treating lobular inflammation and nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH) and NASH-derived hepatocellular carcinoma, with Repirinast.

Key Points: 
  • The invention claims treating lobular inflammation and nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH) and NASH-derived hepatocellular carcinoma, with Repirinast.
  • The base claims of the patent will be valid through 2038, excluding any patent term adjustments or extensions which may provide additional protection.
  • The Company was recently issued patents for Repirinast in NASH from the U.S. and Japan, and has also filed corresponding patent applications in Canada and Europe.
  • “We are pleased to receive this notice of intent to grant from the Chinese Patent Office,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals.